SynBioBeta Speaker
Jodi Barrientos
Ribbon Bio
CEO
Jodi Barrientos is CEO of Ribbon Bio, where she leads the company’s mission to transform how DNA is synthesized and assembled for the next generation of biotechnology innovation. Ribbon Bio is pioneering scalable, high-precision DNA manufacturing technologies that enable researchers and companies to move faster from design to real-world application across therapeutics, agriculture, and industrial biotech.With a strong track record in life sciences leadership, Jodi brings extensive experience in guiding companies through growth, commercialization, and strategic expansion. She is known for her ability to translate complex scientific advancements into practical business outcomes, building high-performing teams and cultivating meaningful partnerships across the biotech ecosystem.At Ribbon Bio, Jodi is helping redefine the production of complex DNA constructs, empowering scientists with tools that accelerate discovery and development. Her work supports a more efficient and accessible bioeconomy, unlocking new opportunities to address global challenges.Jodi is an active leader in the synthetic biology community and is passionate about fostering collaboration, innovation, and the continued advancement of the industry.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jodi
This Year
•
-
Tools & Tech
Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?
For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.
Get a Ticket
Featuring
Andrew Han
GenomeWeb
Editor
GenomeWeb editor covering sequencing and diagnostics markets.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Emily Leproust
Twist Bioscience
CEO
Leader in DNA Manufacturing, put DNA writing on silicon.
Monique Coy
Corteva Agriscience
Program Leader
Jodi Barrientos
Ribbon Bio
CEO
•
-
Tools & Tech
Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?
For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.
Get a Ticket
Featuring
Andrew Han
GenomeWeb
Editor
GenomeWeb editor covering sequencing and diagnostics markets.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Emily Leproust
Twist Bioscience
CEO
Leader in DNA Manufacturing, put DNA writing on silicon.
Monique Coy
Corteva Agriscience
Program Leader
Jodi Barrientos
Ribbon Bio
CEO
•
-
Human Health
Spotlight Brought to you by Ribbon Biolabs
Get a Ticket
Featuring
Jodi Barrientos
Ribbon Bio
CEO
•
-
Human Health
Spotlight Brought to you by Ribbon Biolabs
Get a Ticket
Featuring
Jodi Barrientos
Ribbon Bio
CEO
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
